The epidermal growth factor family has a dual role in deciding the fate of cancer cells

References

• Guy P. M., Platko J. V., Cantley L. C., Cerione R. A., Carraway K. L. Insect cell‐expressed P180(Erbb3) possesses an impaired tyrosine kinase activity. Proc Natl Acad Sci 1994; 91: 8132–6
   PubMed Web of Science ®Google Scholar
• Burden S., Yarden Y. Neuregulins and their receptors: a versatile signaling module in organogenesis and oncogenesis. Neuron 1997; 18: 847–55
   PubMed Web of Science ®Google Scholar
• Ivanov V. N., Hei T. K. Combined treatment with EGFR inhibitors and arsenite upregulated apoptosis in human EGFR‐positive melanomas: a role of suppression of the PI3K‐AKT pathway. Oncogene 2005; 24: 616–26
   PubMed Web of Science ®Google Scholar
• Jorissen R. N., Walker F., Pouliot N., Garrett T. P. J., Ward C. W., Burgess A. W. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res 2003; 284: 31–53
   PubMed Web of Science ®Google Scholar
• Gullick W. J. The type 1 growth factor receptors and their ligands considered as a complex system. Endocrine‐Related Cancer 2001; 8: 75–82
   PubMed Web of Science ®Google Scholar
• Yarden Y., Sliwkowski M. X. Untangling the ErbB signalling network. Nature Rev Mol Cell Biol 2001; 2: 127–37
   PubMed Web of Science ®Google Scholar
• Massague J., Pandiella A. Membrane‐anchored growth factors. Annu Rev Biochem 1993; 62: 515–41
   PubMed Web of Science ®Google Scholar
• Garcia I., Vizoso F., Martin A., Sanz L., Abdel‐Lah O., Raigoso P., et al. Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer. Ann Surg Oncol 2003; 10: 234–41
   PubMed Web of Science ®Google Scholar
• Nielsen T. O., Hsu F. D., Jensen K., Cheang M., Karaca G., Hu Z., et al. Immunohistochemical and clinical characterization of the basal‐like subtype of invasive breast carcinoma. Clin Cancer Res 2004; 10: 5367–74
   PubMed Web of Science ®Google Scholar
• Tovey S. M., Witton C. J., Bartlett J. M., Stanton P. D., Reeves J. R., Cooke T. G. Outcome and human epidermal growth factor receptor (HER) 1‐4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling. Breast Cancer Res 2004; 6: R246–51
   PubMed Web of Science ®Google Scholar
• Memon A. A., Sorensen B. S., Melgard P., Fokdal L., Thykjaer T., Nexo E. Expression of HER3, HER4 and their ligand heregulin‐4 is associated with better survival in bladder cancer patients. Br J Cancer 2004; 91: 2034–41
   PubMed Web of Science ®Google Scholar
• Barnes N. L., Khavari S., Boland G. P., Cramer A., Knox W. F., Bundred N. J. Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast. Clin Cancer Res 2005; 11: 2163–8
   PubMed Web of Science ®Google Scholar
• Sartor C. I., Zhou H., Kozlowska E., Guttridge K., Kawata E., Caskey L., et al. Her4 mediates ligand‐dependent antiproliferative and differentiation responses in human breast cancer cells. Mol Cell Biol 2001; 21: 4265–75
   PubMed Web of Science ®Google Scholar
• Chomczynski P., Sacchi N. Single‐step method of Rna isolation by acid guanidinium thiocyanate phenol chloroform extraction. Anal Biochem 1987; 162: 156–9
   PubMed Web of Science ®Google Scholar
• Schooler K., Wiley H. S. Ratiometric assay of epidermal growth factor receptor tyrosine kinase activation. Anal Biochem 2000; 277: 135–42
   PubMed Web of Science ®Google Scholar
• Kristensen J. K., Lose G., Lund F., Nexo E. Epidermal growth‐factor in urine from patients with urinary‐bladder tumors. Eur Urol 1988; 14: 313–14
   Google Scholar
• Mellon J. K., Cook S., Chambers P., Neal D. E. Transforming growth factor alpha and epidermal growth factor levels in bladder cancer and their relationship to epidermal growth factor receptor. Br J Cancer 1996; 73: 654–8
   PubMed Web of Science ®Google Scholar
• Ravery V., Grignon D., Angulo J., Pontes E., Montie J., Crissman J., et al. Evaluation of epidermal growth factor receptor, transforming growth factor alpha, epidermal growth factor and c‐erbB2 in the progression of invasive bladder cancer. Urol Res 1997; 25: 9–17
   PubMed Web of Science ®Google Scholar
• Vollmer R. T., Humphrey P. A., Swanson P. E., Wick M. R., Hudson M. A. Invasion of the bladder by transitional cell carcinoma – Its relation to histologic grade and expression of p53, MIB‐1, c‐erb B‐2, epidermal growth factor receptor, and bcl‐2. Cancer 1998; 82: 715–23
   Web of Science ®Google Scholar
• Lonn U., Lonn S., Friberg S., Nilsson B., Silfversward C., Stenkvist B. Prognostic value of amplification of c‐erb‐B2 in bladder carcinoma. Clin Cancer Res 1995; 1: 1189–94
   PubMed Web of Science ®Google Scholar
• Arpino G., Green S. J., Allred D. C., Lew D., Martino S., Osborne C. K., et al. HER‐2 amplification, HER‐1 expression, and tamoxifen response in estrogen receptor‐positive metastatic breast cancer: a southwest oncology group study. Clin Cancer Res 2004; 10: 5670–6
   PubMed Web of Science ®Google Scholar
• Blackwell K. L., Dewhirst M. W., Liotcheva V., Snyder S., Broadwater G., Bentley R., et al. HER‐2 gene amplification correlates with higher levels of angiogenesis and lower levels of hypoxia in primary breast tumors. Clin Cancer Res 2004; 10: 4083–8
   PubMed Web of Science ®Google Scholar
• Popov Z., Gil‐Diez‐De‐Medina S., Ravery V., Hoznek A., Bastuji‐Garin S., Lefrere‐Belda M. A., et al. Prognostic value of EGF receptor and tumor cell proliferation in bladder cancer: therapeutic implications. Urol Oncol 2004; 22: 93–101
   PubMed Web of Science ®Google Scholar
• Diermeier S., Horvath G., Knuechel‐Clarke R., Hofstaedter F., Szollosi J., Brockhoff G. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB‐receptor interaction and activation. Exp Cell Res 2005; 304: 604–19
   PubMed Web of Science ®Google Scholar
• Abd El‐Rehim D. M., Pinder S. E., Paish C. E., Bell J. A., Rampaul R. S., Blamey R. W., et al. Expression and co‐expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma. Br J Cancer 2004; 91: 1532–42
   PubMed Web of Science ®Google Scholar
• Barnes N. L., Khavari S., Boland G. P., Cramer A., Knox W. F., Bundred N. J. Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast. Clin Cancer Res 2005; 11: 2163–8
   PubMed Web of Science ®Google Scholar
• Sartor C. I., Zhou H., Kozlowska E., Guttridge K., Kawata E., Caskey L., et al. Her4 mediates ligand‐dependent antiproliferative and differentiation responses in human breast cancer cells. Mol Cell Biol 2001; 21: 4265–75
   PubMed Web of Science ®Google Scholar
• Ritter C. A., Arteaga C. L. The epidermal growth factor receptor‐tyrosine kinase: a promising therapeutic target in solid tumors. Semin Oncol 2003; 30: 3–11
   PubMed Web of Science ®Google Scholar
• Torring N., Jorgensen P. E., Sorensen B. S., Nexo E. Increased expression of heparin binding EGF (HB‐EGF), amphiregulin, TGF alpha and epiregulin in androgen‐independent prostate cancer cell lines. Anticancer Res 2000; 20: 91–5
   PubMedGoogle Scholar
• Banerjee S., Sengupta K., Saxena N. K., Dhar K., Banerjee S. K. Epidermal growth factor induces WISP‐2/CCN5 expression in estrogen receptor‐alpha‐positive breast tumor cells through multiple molecular cross‐talks. Mol Cancer Res 2005; 3: 151–62
   PubMed Web of Science ®Google Scholar
• Barnard J. A., Graves‐Deal R., Pittelkow M. R., DuBois R., Cook P., Ramsey G. W., et al. Auto‐ and cross‐induction within the mammalian epidermal growth factor‐related peptide family. J Biol Chem 1994; 269: 22817–22
   PubMed Web of Science ®Google Scholar
• Inui Y., Higashiyama S., Kawata S., Tamura S., Miyagawa J. I., Taniguchi N., et al. Expression of heparin‐binding epidermal growth‐factor in human hepatocellular‐carcinoma. Gastroenterology 1994; 107: 1799–804
   PubMed Web of Science ®Google Scholar
• Kobrin M. S., Funatomi H., Friess H., Buchler M. W., Stathis P., Korc M. Induction and expression of heparin‐binding EGF‐like growth factor in human pancreatic cancer. Biochem Biophys Res Commun 1994; 202: 1705–9
   PubMed Web of Science ®Google Scholar
• Naef M., Yokoyama M., Friess H., Buchler M. W., Korc M. Co‐expression of heparin‐binding EGF‐like growth factor and related peptides in human gastric carcinoma. Int J Cancer 1996; 66: 315–21
   PubMed Web of Science ®Google Scholar
• Tsai M. S., Shamon‐Taylor L. A., Mehmi I., Tang C. K., Lupu R. Blockage of heregulin expression inhibits tumorigenicity and metastasis of breast cancer. Oncogene 2003; 22: 761–8
   PubMed Web of Science ®Google Scholar
• Nakano N., Higashiyama S., Ohmoto H., Ishiguro H., Taniguchi N., Wada Y. The N‐terminal region of NTAK/neuregulin‐2 isoforms has an inhibitory activity on angiogenesis. J Biol Chem 2004; 279: 11465–70
   Google Scholar
• Penne K., Bohlin C., Schneider S., Allen D. Gefitinib (Iressa, ZD1839) and tyrosine kinase inhibitors: the wave of the future in cancer therapy. Cancer Nurs 2005; 28: 481–6
   Google Scholar
• Ariyama H., Qin B., Baba E., Tanaka R., Mitsugi K., Harada M., et al. Gefitinib, a selective EGFR tyrosine kinase inhibitor, induces apoptosis through activation of Bax in human gallbladder adenocarcinoma cells. J Cell Biochem 2006; 97: 724–34
   PubMed Web of Science ®Google Scholar
• Hara F., Aoe M., Doihara H., Taira N., Shien T., Takahashi H., et al. Antitumor effect of gefitinib (“Iressa”) on esophageal squamous cell carcinoma cell lines in vitro and in vivo. Cancer Lett 2005; 226: 37–47
   PubMed Web of Science ®Google Scholar
• Bieche I., Onody P., Tozlu S., Driouch K., Vidaud M., Lidereau R. Prognostic value of ERBB family mRNA expression in breast carcinomas. Int J Cancer 2003; 106: 758–65
   PubMed Web of Science ®Google Scholar
• Pawlowski V., Revillion F., Hebbar M., Hornez L., Peyrat J. P. Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real‐time reverse transcription‐polymerase chain reaction assay. Clin Cancer Res 2000; 6: 4217–25
   PubMed Web of Science ®Google Scholar